Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oncolytics Biotech Inc (NQ: ONCY )

1.110 -0.020 (-1.78%)
Streaming Delayed Price Updated: 3:39 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 247,938
Open 1.150
Bid (Size) 1.100 (78)
Ask (Size) 1.110 (27)
Prev. Close 1.130
Today's Range 1.100 - 1.150
52wk Range 0.8830 - 3.394
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ONCY Stock Earnings: Oncolytics Biotech Beats EPS for Q1 2024
ONCY stock results show that Oncolytics Biotech beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:ZLAB),(NASDAQ:NTBL),(NASDAQ:CRDF),(NYSE:JNJ) EQNX::TICKER_END 
Via FinancialNewsMedia

Performance

YTD
-15.92%
-15.92%
1 Month
+2.77%
+2.77%
3 Month
-4.32%
-4.32%
6 Month
-21.28%
-21.28%
1 Year
-43.08%
-43.08%

More News

Read More
Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer
Via FinancialNewsMedia
Recap: Oncolytics Biotech Q4 Earnings
Via Benzinga
A Preview Of Oncolytics Biotech's Earnings
Via Benzinga
Biotech Innovations Paving the Way in Breast Cancer Fight
Via FinancialNewsMedia
Topics Death
Exposures Death Product Safety
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
Via FinancialNewsMedia
Exposures Product Safety
Biotech’s Role in Addressing the Pancreatic Cancer Emergency
Via FinancialNewsMedia
ONCY Stock Earnings: Oncolytics Biotech Beats EPS for Q4 2023
Via InvestorPlace
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth
Via FinancialNewsMedia
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning
Via Newsfile
Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
Via FinancialNewsMedia
Earnings Scheduled For March 7, 2024
Via Benzinga
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
Via FinancialNewsMedia
Cancer Immunotherapy Stocks – Tapping into Immune Systems for Next Generation Treatments
Via FinancialNewsMedia
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
From FN Media Group LLC
Via GlobeNewswire
Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments
Via Newsfile
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
Via FinancialNewsMedia
Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort
Via FinancialNewsMedia
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
From FN Media Group LLC
Via GlobeNewswire
Pancreatic Cancer Treatments Poised for Major Advances in 2024
Via FinancialNewsMedia
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
Via FinancialNewsMedia
Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors
Via FinancialNewsMedia
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
From FN Media Group LLC
Via GlobeNewswire
Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024
Via FinancialNewsMedia
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.